Skip to content
Tuesday, November 17, 2026
Latest
Regulation

FDA authorizes ZYN modified-risk claims for 20 variants in US

The FDA authorized modified-risk marketing for 20 ZYN nicotine pouch variants on 11 November 2026, allowing Philip Morris to state lower disease risks than cigarettes for those products only.

A showcar of Kyle Busch's No. 8 Zone nicotine pouches Chevrolet at Nashville Superspeedway in 2025.
A showcar of Kyle Busch's No. 8 Zone nicotine pouches Chevrolet at Nashville Superspeedway in 2025. Photographed 2025-06-01. File photo: Marco Espino-Ovalle / Wikimedia Commons, Public domain. Image: Marco Espino-Ovalle Image source · Public domain · Display crop and size variants; source image content retained.

Key points

  • The FDA authorized modified-risk marketing for 20 ZYN nicotine pouch variants on 11 November 2026.
  • The permitted claim covers lower risks of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis versus cigarettes.
  • The FDA reviewed company applications and evidence under Section 911 of the Federal Food, Drug, and Cosmetic Act.
  • The authorization covers the named variants and wording only and does not mean the products are risk-free.
On this page
  1. Claims are limited to six named conditions
  2. Section 911 review covered adults who switched from cigarettes
  3. The order does not declare the products risk-free
  4. The decision supports Philip Morris’s smoke-free expansion
  5. Manufacturers should read the order as a wording limit, not a category approval
  6. What happens next
  7. Questions readers ask

The FDA authorized modified-risk marketing for 20 ZYN nicotine pouch variants on Wednesday 11 November 2026, letting Philip Morris International make specified lower-risk claims against cigarettes in the US.

The order covers those 20 variants and specific wording only. It does not apply to other ZYN products or to claims the agency has not reviewed.

Claims are limited to six named conditions

The permitted statement refers to lower risks of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis compared with cigarette use, according to the report.

Philip Morris may use that comparison in the US market for the approved products. The authorization sets the boundary of what the company can say, not a general licence to describe the range as low risk.

Section 911 review covered adults who switched from cigarettes

The FDA decision followed a review of company applications and scientific evidence submitted under Section 911 of the Federal Food, Drug, and Cosmetic Act.

The evidence cited included information on adults who smoked cigarettes and later began using ZYN pouches. The source does not report how many applications were filed, how many were refused, or what data the agency weighed against the company’s submissions.

The order does not declare the products risk-free

Nicotine remains addictive, and the authorization is not an endorsement for non-smokers, the report states.

That distinction matters for labelling and advertising review: a modified-risk order permits a comparative claim, while a statement that the products carry no risk would fall outside it.

The decision supports Philip Morris’s smoke-free expansion

The authorization gives the company a permitted regulatory framework for communicating the cigarette comparison in the US, while restricting it to the authorized variants and wording.

Smoke-free products sit at the centre of Philip Morris International’s strategy of expanding beyond combustible cigarettes, according to the report. The company’s ISIN is listed as US7181721090.

Manufacturers should read the order as a wording limit, not a category approval

Analysis: the order applies product by product and claim by claim, so compliance work centres on matching advertising copy, packaging inserts and retail materials to the authorized wording for each variant.

For suppliers, the practical effect is that comparative risk language has a documented US reference point for one brand’s pouches, while the same language for other products remains unauthorized unless separately reviewed.

What happens next

Philip Morris can now deploy the permitted claim for the 20 variants in the US. The source does not state an expiry date for the order, any transition period for existing materials, or a date for further FDA decisions on ZYN applications.

Item Detail
Decision date 11 November 2026
Products covered 20 ZYN nicotine pouch variants
Legal basis Section 911, Federal Food, Drug, and Cosmetic Act
Conditions named in the permitted claim Mouth cancer, heart disease, lung cancer, stroke, emphysema, chronic bronchitis
Company Philip Morris International Inc., ISIN US7181721090

Questions readers ask

Does the FDA order mean ZYN pouches are risk-free?

No. The report states the order does not mean the products are risk-free or that nicotine use is safe, and that nicotine remains addictive.

Which ZYN products does the authorization cover?

The order covers 20 ZYN nicotine pouch variants and limits claims to those authorized variants and wording.

Share

Sources

18+ only. This site is for adult readers and provides news and information only. It is not medical, legal or purchase advice. Nicotine is addictive. Always check the official text of any regulation in your market. Health Information

VapeBrief Policy Desk

A shared VapeBrief publication label for policy coverage, not a named person or a claim about team size, credentials or legal expertise.

About this byline →

Daily Brief newsletter

A concise email at 08:00 U.S. Eastern time each day, with links to the previous day’s published briefs.

Topics of interest

Active immediately, no confirmation click needed. Every email includes an unsubscribe link. See our Privacy Policy.